Study Enrollment

Your details will not be published or shared.

Clinical Trial

(Bayer Elagolix) A randomized, double-blind, open for active comparator, parallel-group, multicenter Phase 2b study to assess the efficacy and safety of three different doses of P2X3 antagonist (BAY 1817080) versus placebo and elagolix 150 mg in women with symptomatic endometriosis

This study is to see if a new drug is safe and effective in for women treated for endometriosis. It will compare this new drug with Elagolix and with standard treatment only.

Eligibility Criteria

  • Premenopausal women above the age of 18 years who have moderate to severe pain associated with endometriosis diagnosed by laparoscopy/laparotomy, ultrasound, or MRI.

Contact Information

    Soumia Brakta, MD

    706 721-3832